Edition:
United Kingdom

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

65.97USD
23 Aug 2019
Change (% chg)

$-1.55 (-2.30%)
Prev Close
$67.52
Open
$67.29
Day's High
$67.77
Day's Low
$65.49
Volume
2,878,860
Avg. Vol
2,181,684
52-wk High
$98.69
52-wk Low
$62.68

Latest Key Developments (Source: Significant Developments)

Abbvie Receives FDA Approval Of Rinvoq (Upadacitinib) For Treatment Of Moderate To Severe Rheumatoid Arthritis
Friday, 16 Aug 2019 

Aug 16 (Reuters) - Abbvie Inc ::ABBVIE RECEIVES FDA APPROVAL OF RINVOQ™ (UPADACITINIB), AN ORAL JAK INHIBITOR FOR THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS.ABBVIE INC - RINVOQ IS EXPECTED TO BE AVAILABLE IN U.S. IN LATE AUGUST 2019.  Full Article

FDA Approves Abbvie's Rinvoq (Upadacitinib) For Arthritis Treatment
Friday, 16 Aug 2019 

Aug 16 (Reuters) - U.S. Food and Drug Administration::FDA - APPROVES NDA FOR ABBVIE'S RINVOQ (UPADACITINIB) FOR TREATMENT OF RHEUMATOID ARTHRITIS.FDA SAYS ABBVIE'S RINVOQ (UPADACITINIB) COMES WITH A BOXED WARNING.FDA SAYS ABBVIE'S RINVOQ (UPADACITINIB) COMES WITH A BOXED WARNING ABOUT SERIOUS INFECTIONS, MALIGNANCY, AND THROMBOSIS.  Full Article

Allergan Reports Q2 Loss Per Share of $5.37
Tuesday, 6 Aug 2019 

Aug 6 (Reuters) - Allergan Plc ::ALLERGAN REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 GAAP LOSS PER SHARE $5.37.Q2 EARNINGS PER SHARE ESTIMATE $4.34 -- REFINITIV IBES DATA.RAISES GUIDANCE FOR FULL-YEAR 2019 NET REVENUE.REAFFIRMS GUIDANCE FOR FULL-YEAR 2019 PERFORMANCE NET INCOME PER SHARE.Q2 REVENUE FELL 0.8 PERCENT TO $4.09 BILLION.QTRLY NON-GAAP PERFORMANCE NET INCOME PER SHARE OF $4.38.RESTASIS NET REVENUE IN Q2 2019 WERE $310.9 MILLION, A DECREASE OF 2.3 PERCENT.SEES 2019 TOTAL NET REVENUES $15.425 BILLION TO $15.625 BILLION.SEES 2019 LOSS PER SHARE OF MORE THAN $12.03.SEES 2019 NON-GAAP TOTAL NET REVENUE OF $15.4 BILLION - $15.6 BILLION.DUE TO PROPOSED ACQUISITION OF ALLERGAN BY ABBVIE, ALLERGAN IS NOT HOSTING A CONFERENCE CALL TO DISCUSS ITS Q2 RESULTS.FY2019 EARNINGS PER SHARE VIEW $16.72, REVENUE VIEW $15.34 BILLION -- REFINITIV IBES DATA.Q2 2019 GAAP REVENUES AND EXPENSES IMPACTED BY VOLUNTARY GLOBAL RECALL OF BIOCELL TEXTURED BREAST IMPLANTS.RECORDED TOTAL PRE-TAX IMPAIRMENT CHARGES OF $1.65 BILLION FOR QUARTER.TOTAL PRE-TAX IMPAIRMENT CHARGES FOR QUARTER INCLUDES GOODWILL IMPAIRMENT OF $1.09 BILLION IN GENERAL MEDICINE REPORTING UNIT.  Full Article

Allergan Reports Second Quarter 2019 Financial Results
Tuesday, 6 Aug 2019 

Aug 6 (Reuters) - Allergan Plc ::ALLERGAN REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 GAAP LOSS PER SHARE $5.37.Q2 EARNINGS PER SHARE ESTIMATE $4.34 -- REFINITIV IBES DATA.RAISES GUIDANCE FOR FULL-YEAR 2019 NET REVENUE.REAFFIRMS GUIDANCE FOR FULL-YEAR 2019 PERFORMANCE NET INCOME PER SHARE.Q2 REVENUE FELL 0.8 PERCENT TO $4.09 BILLION.QTRLY NON-GAAP PERFORMANCE NET INCOME PER SHARE OF $4.38.RESTASIS NET REVENUE IN Q2 2019 WERE $310.9 MILLION, A DECREASE OF 2.3 PERCENT.SEES 2019 TOTAL NET REVENUES $15.425 BILLION TO $15.625 BILLION.SEES 2019 LOSS PER SHARE OF MORE THAN $12.03.SEES NON-GAAP TOTAL NET REVENUE OF $15.4 BILLION - $15.6 BILLION.DUE TO PROPOSED ACQUISITION OF ALLERGAN BY ABBVIE, ALLERGAN IS NOT HOSTING A CONFERENCE CALL TO DISCUSS ITS Q2 RESULTS.2019 GAAP REVENUES AND EXPENSES IMPACTED BY VOLUNTARY GLOBAL RECALL OF BIOCELL TEXTURED BREAST IMPLANTS.FY2019 EARNINGS PER SHARE VIEW $16.72, REVENUE VIEW $15.34 BILLION -- REFINITIV IBES DATA.  Full Article

AbbVie Submits New Drug Application To U.S. FDA For Investigational Elagolix For Management Of Heavy Menstrual Bleeding Associated With Uterine Fibroids In Women
Monday, 5 Aug 2019 

Aug 5 (Reuters) - AbbVie Inc ::ABBVIE SUBMITS NEW DRUG APPLICATION TO US FDA FOR INVESTIGATIONAL ELAGOLIX FOR MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS IN WOMEN.ABBVIE INC - NEW DRUG APPLICATION IS SUPPORTED BY DATA FROM PIVOTAL PHASE 3 STUDIES OF NEARLY 800 PATIENTS.  Full Article

AbbVie'S Director Roxanne Austin Reports Open Market Purchase Of 30,000 Shares At Average Price Of $66.02 Per Share
Friday, 2 Aug 2019 

Aug 2 (Reuters) - AbbVie Inc ::ABBVIE INC SAYS DIRECTOR ROXANNE AUSTIN REPORTS OPEN MARKET PURCHASE OF 30,000 SHARES AT AVERAGE PRICE OF $66.02PER SHARE ON JULY 31 - SEC FILING.ABBVIE INC SAYS DIRECTOR ROXANNE AUSTIN REPORTS OPEN MARKET PURCHASE OF 25,000 SHARES AT AVERAGE PRICE OF $65.66PER SHARE ON AUGUST 1.  Full Article

Abbvie Reports Qtrly EPS Of $0.49
Friday, 26 Jul 2019 

July 26 (Reuters) - AbbVie Inc ::ABBVIE QTRLY GAAP EARNINGS PER SHARE $0.49; QTRLY ADJUSTED EARNINGS PER SHARE $2.26.QTRLY NET REVENUE $8.26 BILLION VERSUS $8.28 BILLION.SAYS IS RAISING REVENUE AND ADJUSTED EPS GUIDANCE FOR 2019.Q2 EARNINGS PER SHARE VIEW $2.21, REVENUE VIEW $8.10 BILLION -- REFINITIV IBES DATA.UPDATES 2019 GAAP EARNINGS PER SHARE GUIDANCE RANGE FROM $7.26 TO $7.36 TO $5.69 TO $5.79.FY2019 EARNINGS PER SHARE VIEW $8.82 -- REFINITIV IBES DATA.RAISES 2019 ADJUSTED EARNINGS PER SHARE GUIDANCE RANGE FROM $8.73 TO $8.83 TO $8.82 TO $8.92.QTRLY GLOBAL HUMIRA NET REVENUE OF $4.87 BILLION, DOWN 6.1% ON A REPORTED BASIS.QTRLY GLOBAL IMBRUVICA NET REVENUE $1,099 MILLION, UP 29.3%.IN U.S., QTRLY HUMIRA NET REVENUE OF $3.79 BILLION, UP 7.7%.INTERNATIONALLY, Q2 HUMIRA NET REVENUE OF $1.08 BILLION, DOWN 35.2% ON REPORTED BASIS, OR 31% OPERATIONALLY, DUE TO BIOSIMILAR COMPETITION.IN Q2 RECORDED A $2.3 BILLION INCREASE IN FAIR VALUE OF CONTINGENT CONSIDERATION RELATED TO SKYRIZI FUTURE MILESTONES, ROYALTY PAYMENTS.QTRLY TOTAL SKYRIZI NET REVENUE $48 MILLION.  Full Article

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Empliciti Plus Pomalidomide And Low-Dose Dexamethasone
Friday, 26 Jul 2019 

July 26 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB RECEIVES POSITIVE CHMP OPINION RECOMMENDING APPROVAL OF EMPLICITI (ELOTUZUMAB) PLUS POMALIDOMIDE AND LOW-DOSE DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA.BRISTOL-MYERS SQUIBB - CO & ABBVIE ARE TOGETHER DEVELOPING EMPLICITI, WITH CO SOLELY RESPONSIBLE FOR COMMERCIAL ACTIVITIES.  Full Article

AbbVie Says Entered Term Loan Credit Agreement
Tuesday, 16 Jul 2019 

July 16 (Reuters) - AbbVie Inc ::ABBVIE SAYS ENTERED TERM LOAN CREDIT AGREEMENT.ABBVIE - AGREEMENT PROVIDES UNSECURED TERM LOAN FINANCING CONSISTING OF A $1.5 BILLION 364-DAY TERM LOAN TRANCHE.ABBVIE - AGREEMENT PROVIDES UNSECURED TERM LOAN FINANCING CONSISTING OF A $2.5 BILLION 3-YEAR TERM LOAN TRANCHE.ABBVIE - AGREEMENT ALSO PROVIDES UNSECURED TERM LOAN FINANCING CONSISTING OF A $2.0 BILLION 5-YEAR TERM LOAN TRANCHE.  Full Article

Elliott management advocated for an Allergan split prior to sale - Bloomberg Reporter Tweet
Wednesday, 26 Jun 2019 

June 26 (Reuters) - :ELLIOTT HAD BUILT STAKE IN ALLERGAN WAS ADVOCATING FOR BREAK UP OF CO PRIOR TO IT ANNOUNCING PLANS TO BE ACQUIRED BY ABBVIE - BLOOMBERG REPORTER TWEET.  Full Article

Photo

Factbox: Pending mergers and acquisitions involving U.S. firms that need Chinese approval

NEW YORK U.S. President Donald Trump said on Friday he has ordered American companies to exit China after Beijing unveiled retaliatory tariffs on $75 billion worth of U.S. goods, in a new twist in the bitter trade war between the world's two largest economies.